We were recently invited to provide a case study for BritishAmerican Business (BAB), a transatlantic network supporting trade relations between the US and UK.

The approach we chose to take was one that enabled us to share our predilection for collaborative working relationships. We like things that make it easier for us to work together on a global scale; why not extend our community? Yet we remain mindful that this must always be in the interests of providing access to improved commodities and service delivery.

In this case study we explore how and why a collaborative approach to global trade can work in support of best practice and continued improvement in healthcare delivery.

You can read our Case Study here: BAB/ Bluekit Medical

Also available in Four Sectors, Many Stories, One Ambition.

For our extended article, please read on and enjoy.

We all want reliable and resilient healthcare: A safe patient journey. Healthcare practitioners want this too, and like us, they want to invest in long-term strategy, providing healthcare that supports preventative measures and affords to prepare for our future.

Fortunately, investment of this kind is cost-effective too. Getting it right the first time, reduces waste, avoids compromise and promotes safety.

At Bluekit Medical, we want everybody to get onboard with this idea. With a comprehensive range of medical and surgical procedure packs, drape packs and surgical consumables in the hands of healthcare providers, our products are designed to represent, promote and embed a culture of reliable and resilient healthcare delivery.

In the US today, emphasis in healthcare delivery is also shifting to protection, preparation and prevention. A large part of this challenge is proven to depend on the standardisation and harmonisation of products and practices.

In our experience, exporting medical devices to the US presents an array of divergent regulatory requirements demanding careful navigation to achieve confident compliance. Bluekit products are exposed to FDA approval, increased risk of product liability due to US labelling and packaging guidelines, and greater insurance and exporting costs.

When the standardisation and harmonisation of regulatory frameworks and product classifications can directly assist in the effective provision of goods for medical and surgical practice, it seems only fitting that we should find increasingly better methods of denomination, encouraging global interaction, not determinable only by local knowledge, but supplemented with cohesive systems, such as that operating across the EU.

The healthcare demands of the US are much like our own, and with similar ambitions we are able to learn from each other and drive forward innovation in life sciences. For Bluekit Medical, the US market presents a fantastic opportunity that we have only just begun to explore with the help of local distributorship. We would like to see policy that nurtures this relationship, supports best practice and encourages opportunity.